On the basis of this result, a phase III trial evaluating the efficacy and safety of JSKN003 in treating unresectable locally advanced or metastatic HER2-low-expressing breast cancer has recently been initiated (JSKN003-302). Here, ERBB2 is linked to breast carcinoma.